Avidicure
Avidicure is developing dual agonistic avidity-engineered multifunctional antibodies, AVC-Boosters, as monotherapy for treatment of cancer
$50M Seed ·
Led by EQT Life Sciences · Source: fundraisingfox.com
Funding history ↓Signals
Website registeredApr 20, 2022 (4 years old)
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Seed | $50M | fundraisingfox.com |
Timeline
- Website created
Founders and team
GS
Govert Schouten FounderRF
Robert Friesen FounderAL
Arthur Lahr Chief Executive OfficerDN
Dirk Naeyer Chief Operating OfficerON
Oliver Nussbaumer Senior Vice President
Investors
BBioGeneration Ventures
BBOM
CCurie Capital
EEQT Life Scienceslead investor
KKurma Partners
VV-Bio Ventures
Companies like Avidicure
AAnaveon$120M Series B+ · Dec 2021
DDren Bio$350M Series B+ · Oct 2026SSynthekine$100M Series B+ · Jan 2023
NNormunity$75M Series B+ · Jan 2025
MMemo Therapeutics$22M Series B+ · May 2024
GGenomadixSeed · Jul 2022
Other companies backed by EQT Life Sciences
NNouscom$135.04M Series B+ · Oct 2026
VVaderis Therapeutics$152M Series B+ · Aug 2026
RRQ Bio$115M Series A · Jun 2026
KKinaset Therapeutics$103M Series B+ · Jan 2026
FFoRx Therapeutics$50M Series A · Dec 2025
TTubulis$360M Series B+ · Oct 2025
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/avidicure (get a free API key).